Pfizer (PFE) Rides MRNA Cancer Optimism On A Valuation That Still Looks Modest
Pfizer (PFE) has gained renewed investor interest due to positive Phase 3 results for an mRNA melanoma treatment, boosting optimism for its oncology-focused mRNA pipeline. While the stock has seen short-term gains, longer-term recovery is still sought, with a modest 3% difference from the average analyst target. Despite a current "undervalued" narrative placing its fair value at $29.19 per share, Simply Wall St's DCF model suggests a significantly higher value of $73.31, indicating a material undervaluation.
Jazz Pharmaceuticals (JAZZ) As HER2 Pipeline Progress Fuels An Undervalued Narrative
Jazz Pharmaceuticals (JAZZ) is gaining investor attention due to its HER2 pipeline progress, particularly for gastroesophageal adenocarcinoma, and is currently deemed 11.6% undervalued with a fair value of $281.35. Despite a recent share price pullback, the company shows strong year-to-date and one-year returns, driven by R&D, commercialization efforts, and international expansion, although potential risks like generic pressure and trial underperformance exist.
Moderna's Comeback Is Finally Taking Shape -- and There May Be More Upside Ahead
Moderna's shares have surged 402% this year due to significant clinical and regulatory progress. The company received FDA approval for mFLUSIVA, a more effective flu vaccine, and posted strong phase 3 results for its personalized cancer vaccine, intismeran autogene, leading to further stock gains. Despite its current unprofitability and large market cap, Moderna's deep pipeline and potential for future product launches make it an attractive long-term investment.
Can Merck & Company (MRK)’s Stake in Evaxion A/S (EVAX) Validate the Potential of AI-Driven Vaccine Discovery?
Merck & Company (MRK) has disclosed a significant stake in Evaxion A/S (EVAX), an AI immunology firm, following Merck's decision to in-license Evaxion's AI-discovered vaccine candidate, EVX-B3. This move by a major pharmaceutical company provides credibility for Evaxion's AI-driven vaccine discovery platform, despite the financial disparity between the mega-cap Merck and the pre-revenue biotech Evaxion. Investors are now watching for further preclinical progress for Evaxion and integration of acquisitions for Merck.
Bristol-Myers Squibb Co Stock (BMY) Closed Down by 3.17% on Aug 20: Facts Behind the Movement
Bristol-Myers Squibb Co (BMY) stock closed down by 3.17% on August 20, primarily due to profit-taking after a multi-week rally and concerns over looming patent expirations on legacy treatments. Despite strong Q2 earnings and regulatory approvals, investors are balancing these positives against long-term structural risks, including potential revenue contraction and significant debt. Technical indicators suggest mixed signals, while fundamental analysis highlights the company's substantial revenue and profit within the Pharmaceuticals & Medical Research industry.
The Options Market Gives Synopsys Room To Fall Two-Fifths Or Rise Two-Thirds
The options market indicates that Synopsys (SNPS) has a potential price band with a floor near $240 and a ceiling near $665 over the next thirteen months, representing a possible fall of two-fifths or a rise of two-thirds from its current price of $401. Despite this wide range, the implied volatility in the options market is lower than the stock's realized volatility over the past year, suggesting that the market is not bracing for heightened fear. This perceived "calm" is notable given upcoming events like Q3 earnings and the initial revenue test for the Ansys deal, whose synergies begin in fiscal 2027.
Virtus Biotech ETF (BBP) rated buy for strong biotech exposure and recent gains amid sector growth.
The Virtus Biotech ETF (BBP) is recommended as a buy due to its focused investment in FDA-approved biotech companies, strong recent performance, and an equal-weight, quarterly rebalancing strategy. Despite challenges like rising interest rates, growth in biotech sector deals and the GLP-1 market support a positive outlook. Its concentrated portfolio and cost efficiency make it attractive for long-term investors seeking biotech exposure.
Why Iovance Biotherapeutics Stock Hit 52-Week High
Iovance Biotherapeutics (NASDAQ: IOVA) stock reached a 52-week high despite no new company-specific news, largely attributed to breakthrough data from Moderna and Merck & Co's individualized cancer therapy for advanced skin cancer. Iovance's own Amtagvi, an FDA-approved TIL therapy for advanced melanoma, and positive early data for its TIL cell therapy in soft-tissue sarcomas also contribute to investor interest, along with strong Q2 earnings and raised price targets from analysts.
Merck & Co., Inc. (NYSE:MRK) Price Target Raised to $170.00
BMO Capital Markets raised Merck & Co., Inc.'s (NYSE:MRK) price target to $170.00 from $142.00, maintaining an "outperform" rating with a potential upside of 12.49%. This comes amidst mixed analyst sentiment, although the consensus rating remains "Moderate Buy" with an average target of $142.10. The company's recent quarterly results surpassed expectations, and its Keytruda-personalized cancer vaccine program shows promise, despite significant insider stock sales.
Tempus AI Inc Stock (TEM) Moved Up by 10.87% on Aug 20: What Signal Does It Send?
Tempus AI Inc (TEM) saw its stock rise by 10.87% on August 20, driven by positive Phase 3 trial results for individualized mRNA cancer vaccines from Merck and Moderna, which validated Tempus AI's acquisition of Personalis. The stock also benefited from a reaffirmed Buy rating and raised price target from BTIG Research, strong quarterly earnings, and a short squeeze due to elevated short interest. However, the company faces risks such as equity dilution from the Personalis acquisition, insider stock liquidation, negative free cash flow, and analyst valuation caps.
Moderna Sinks 18% After 177% Cancer Vaccine Rally, BioNTech Falls 4%, Merck Slips
Moderna shares dropped 18% on Thursday, partially reversing a significant 177% rally from the previous day, following a Phase 3 win for its personalized cancer vaccine. BioNTech also fell 4% due to reduced enthusiasm for mRNA oncology read-across, while Merck, co-owner of the trial, saw a minor 1% slip. The market's reaction reflects that the success in adjuvant melanoma was already largely priced into Moderna's stock, with future validation depending on the complete data presentation at ESMO in October.
Personalis stock reaches 52-week high at 16.42 USD
Personalis Inc. (PSNL) stock has reached a 52-week high of $16.42, reflecting a strong performance with a 240.73% 1-year total return. Despite this, InvestingPro suggests the stock may be overvalued relative to its Fair Value. The company is set to be acquired by Tempus AI Inc. in an all-stock transaction valued at $1.5 billion, and has also received UK regulatory clearance for its NeXT Personal Dx test.
Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (AMLX), Moderna (MRNA) and Merck & Company (MRK)
The article discusses differing analyst opinions on three healthcare companies: Amylyx Pharmaceuticals Inc (AMLX), Moderna (MRNA), and Merck & Company (MRK). Amylyx received a "Strong Buy" consensus with a significant upside, while Moderna was rated "Hold" with one analyst maintaining a "Sell." Merck & Company also received a "Strong Buy" consensus, despite one analyst's price target implying a slight downside.
Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (AMLX), Moderna (MRNA) and Merck & Company (MRK)
Analysts are divided on several healthcare companies, including Amylyx Pharmaceuticals Inc (AMLX), Moderna (MRNA), and Merck & Company (MRK). While Amylyx and Merck received predominantly positive ratings, Moderna was met with a Sell rating from J.P. Morgan, contributing to an overall Hold consensus. This report details specific analyst recommendations, price targets, and success rates for each company.
Merck & Co., Inc. (NYSE:MRK) Downgraded to "Sector Perform" Rating by Royal Bank Of Canada
Royal Bank of Canada downgraded Merck & Co., Inc. (NYSE:MRK) from an "outperform" to a "sector perform" rating, setting a $150 price target, which implies a slight downside from its current price. Despite this downgrade, the overall analyst sentiment remains positive, with a "Moderate Buy" consensus and an average price target of $139.20. The company recently exceeded earnings and revenue expectations, and its shares are trading near their 52-week high, although insiders have sold almost $30 million in stock over the past 90 days.
Merck & Co., Inc. (NYSE:MRK) Raised to Overweight at Morgan Stanley
Morgan Stanley upgraded Merck & Co., Inc. (NYSE:MRK) from "equal weight" to "overweight" and increased its price target from $116 to $179, suggesting a 17.6% upside. This upgrade follows positive late-stage results for Merck's personalized melanoma vaccine combined with Keytruda, which strengthens its oncology pipeline. Despite some analyst downgrades, the overall sentiment remains "Moderate Buy" with an average price target of $138.80, and institutional investors are actively adjusting their stakes in the company.
Here Are Thursday’s Top Wall Street Analyst Research Calls: Alphabet, Analog Devices, Crown Castle, Ebay, EPR Properties, Etsy, Merck & Co., Shopify, TJX Companies, and More
This article details Wall Street analyst upgrades, downgrades, and new initiations for several major companies on Thursday, August 20, 2026. Key actions include Morgan Stanley upgrading Merck & Co. and Rosenblatt initiating Buy ratings on Alphabet, eBay, and Shopify. The report also provides a market recap, highlighting the impact of Treasury Secretary Bessent's announcement to double bond buybacks, which led to a rally in gold, a drop in Treasury yields, and an increase in major stock indices.
Merck is a buy as strong cancer drug pipeline offsets Keytruda patent expiration, Morgan Stanley says
Morgan Stanley has upgraded Merck's stock to overweight, raising its price target to $179, citing a strong cancer drug pipeline that is expected to drive growth even after its blockbuster drug Keytruda's patent expires in 2028. The firm believes new drugs and potential Keytruda co-formulations will mitigate the impact of the patent expiration and support future share growth. Merck's stock has already seen a significant jump this year due to positive clinical trial results for its investigational drugs.
Merck & Co., Inc. (NYSE:MRK) Stock Rating Lowered by Jefferies Financial Group
Jefferies Financial Group has downgraded Merck & Co., Inc. (NYSE:MRK) from a "strong-buy" to a "hold" rating, despite a broader analyst consensus of "moderate buy." The downgrade follows Merck's recent positive Phase 3 results for a personalized melanoma vaccine combined with Keytruda, which presents a significant growth opportunity, but also comes with regulatory and patent expiry risks. The company exceeded Q2 earnings and revenue expectations, and analysts project a full-year EPS of approximately $2.77.
RBC Capital downgrades Merck & Co as profit-taking hits the stock
RBC Capital has downgraded Merck & Co to "sector perform" from "outperform" due to profit-taking after a significant surge in its stock price. Despite raising the price target to $150, analysts noted that Merck's current valuation already prices in substantial optimism, leaving limited upside, especially with a major patent loss looming within two years. The firm acknowledges the strong momentum but believes the risk-reward profile is now fairly valued.
Goldman Sachs Adjusts Price Target on Merck & Co. to $160 From $140, Keeps Buy Rating
Goldman Sachs has increased its price target for Merck & Co. (MRK) to $160 from $140, while maintaining a Buy rating on the stock. This adjustment reflects a positive outlook from the investment bank for the pharmaceutical giant. The news comes amid several other analyst updates for Merck, including other price target adjustments and rating changes.
William Blair initiates Surrozen stock with Outperform rating By Investing.com
William Blair has initiated coverage on Surrozen Inc. (NASDAQ:SRZN) with an Outperform rating and a fair value estimate of $51 per share, citing its promising pipeline of multispecific antibodies for retinal diseases. Despite the stock trading at $24.01 with a 109% return over the past year, InvestingPro analysis suggests it may be overvalued relative to its fair value, though analysts maintain a strong buy consensus. This initiation follows H.C. Wainwright's reiterated buy rating for Surrozen, emphasizing confidence in the company's clinical developments, including its lead candidate SZN-8141 for diabetic macular edema.
Wealthfront Advisers LLC Sells 6,410 Shares of Amgen Inc. $AMGN
Wealthfront Advisers LLC decreased its stake in Amgen Inc. by 7.1% in the second quarter, selling 6,410 shares but still retaining 84,152 shares valued at approximately $30.5 million. Amgen reported strong Q2 earnings and revenue, exceeding consensus estimates, and declared a quarterly dividend of $2.52 per share. Despite the stock trading near its 52-week high, analyst sentiment remains mixed with an average "Hold" rating and a price target below current trading levels.
Main Street Financial Solutions LLC Takes $1.66 Million Position in Amgen Inc. $AMGN
Main Street Financial Solutions LLC has acquired a new stake in Amgen Inc., purchasing 4,589 shares valued at approximately $1.66 million. Amgen reported strong Q2 earnings, beating analyst estimates with $6.29 EPS and $10.05 billion in revenue, and declared a quarterly dividend of $2.52 per share. Institutional investors collectively own 76.5% of Amgen's stock, while analysts maintain a "Hold" rating with an average price target of $379.36.
Morgan Stanley Upgrades Merck & Co. to Overweight From Equalweight, Adjusts PT to $179 From $116
Morgan Stanley has upgraded Merck & Co. (MRK) from Equalweight to Overweight, simultaneously increasing its price target for the pharmaceutical company to $179 from $116. This positive revision reflects a more optimistic outlook on Merck's stock performance. The article also notes similar upgrades and price target adjustments from BMO Capital and Jefferies, indicating a broader positive sentiment among analysts for Merck & Co.
Amgen Inc. $AMGN Shares Sold by Danske Bank A S
Danske Bank A S reduced its holdings in Amgen Inc. by 6.8% in the second quarter, selling 29,273 shares, though other institutional investors like Norges Bank and BlackRock Inc. significantly increased their stakes. The article also details recent analyst ratings, Amgen's strong financial performance including a raised dividend, and insider share sales by SVP Nancy A. Grygiel and SVP Rachna Khosla.
Amgen Inc. $AMGN Shares Sold by Great Lakes Advisors LLC
Great Lakes Advisors LLC decreased its holdings in Amgen Inc. by 15.6% in the second quarter, selling 19,901 shares but still retaining 107,992 shares valued at $39.1 million. Despite this sale, institutional investors collectively own 76.5% of Amgen's stock. The company exceeded analyst expectations with its recent earnings report, posting $6.29 EPS and $10.05 billion in revenue, and has a consensus "Hold" rating from analysts with a target price below its current trading value.
Here Are Thursday’s Top Wall Street Analyst Research Calls: Alphabet, Analog Devices, Crown Castle, Ebay, EPR Properties, Etsy, Merck & Co., Shopify, TJX Companies, and More
This article details top Wall Street analyst research calls from Thursday, August 20, 2026, featuring upgrades for companies like Analog Devices, Crown Castle, Etsy, EPR Properties, and Merck & Co. Downgrades include Allstate, Cactus, Coty, Liberty Latin America, and TJX Companies, while Alphabet, eBay, Incyte, Madison Square Garden Entertainment, and Shopify received new "Buy" or "Neutral" initiations. The report also provides a market overview, noting movements in stock futures, Treasury bonds, oil and gas, gold, and cryptocurrencies following a significant bond buyback announcement.
Benjamin Edwards Inc. Purchases 28,700 Shares of Johnson & Johnson $JNJ
Benjamin Edwards Inc. has increased its stake in Johnson & Johnson (NYSE:JNJ) by 21.8%, purchasing an additional 28,700 shares. This transaction brings their total holdings to 160,633 shares valued at $40.79 million. Other institutional investors have also adjusted their positions in JNJ, while company insiders have recently sold shares.
Guggenheim initiates CalciMedica stock coverage with buy rating
Guggenheim has initiated coverage on CalciMedica Inc. (NASDAQ:CALC) with a buy rating and a $9.00 price target, citing excitement for its oral Orai1 inhibitor, CM5480, for pulmonary hypertension. The company's unique clinical-stage program targets a mechanism independent of approved therapies, with data expected by mid-2028. Despite a recent earnings miss, CalciMedica's strategic advancements in its pulmonary hypertension program are attracting investor attention.
Out of sight, out of work? What’s driving remote job cuts
Some biopharma companies are reducing their remote workforce, forcing employees to choose between returning to the office, relocating, or resigning, as seen with EMD Serono and Exelixis. While many employers cite collaboration benefits for requiring on-site presence, other factors like program cuts or cost reductions also drive layoffs, affecting both remote and on-site staff. Experts suggest that job security remains a general industry risk, regardless of work location, though some candidates are wary of changing remote work policies.
TD Cowen Adjusts Price Target on Workday to $220 From $155, Maintains Hold Rating
TD Cowen has increased its price target for Workday (NASDAQ: WDAY) shares to $220 from $155, while maintaining a Hold rating on the stock. This adjustment reflects a significant positive revision in the analyst's outlook for the company. The article also lists other recent analyst adjustments for Workday, with several firms raising their price targets but some also downgrading the stock.
RBC Downgrades Merck & Co. to Sector Perform From Outperform, Adjusts PT to $150 From $142
RBC has downgraded Merck & Co. (MRK) from an "Outperform" rating to "Sector Perform." The bank also adjusted its price target for Merck & Co. shares, raising it to $150 from the previous $142. This change in rating and price target was reported on August 20, 2026.
Moderna or Merck: Which Soaring Cancer Vaccine Stock Is the Better Buy?
Moderna and Merck announced a significant breakthrough with their personalized mRNA cancer vaccine, intismeran autogene, which in combination with Keytruda, met primary and secondary endpoints in a Phase 3 melanoma study. This news caused both stocks to surge, with Moderna more than doubling and Merck jumping over 10%. The article discusses the investment case for each company, highlighting Moderna's higher upside potential but also greater risk due to unprofitability, while Merck offers stronger fundamentals and incremental upside to an already robust oncology platform.
Stock Market Today, Aug. 19: Moderna Skyrockets 177% on Positive Phase 3 Melanoma Data
Moderna's stock surged by 177% following the announcement of positive Phase 3 data for its melanoma treatment, intismeran autogene, when paired with Merck's KEYTRUDA. This significant increase in share price reflects investor optimism about the potential for intismeran in other cancer trials. The news also positively impacted other biotechnology stocks like BioNTech SE and Pfizer.
Vertex Pharmaceuticals Inc Stock (VRTX) Closed Up by 4.48% on Aug 19: Drivers Behind the Movement
Vertex Pharmaceuticals Inc (VRTX) stock closed up by 4.48% on August 19, driven by the failure of a rival's cystic fibrosis clinical trial, strong Q2 revenue that beat estimates, and raised full-year guidance. The company's market leadership in cystic fibrosis and strategic diversification efforts have also contributed to bullish analyst ratings and increased institutional buying. Despite this, the company faces risks such as revenue concentration, operating expense pressure, and valuation premium.
AstraZeneca PLC Stock (AZN) Moved Up by 3.40% on Aug 19: What Signal Does It Send?
AstraZeneca (AZN) stock rose by 3.40% due to positive Phase III oncology trial results for Tagrisso/Orpathys and Enhertu, which garnered bullish analyst commentary. Fading rumors of a merger with Bristol Myers Squibb also shifted investor focus back to AstraZeneca's strong organic growth and robust drug portfolio. The company reported annual revenue of $58.74 billion and a net profit of $10.22 billion.
Which Drugmaker Stock Has Dominated in 2026: Merck, Pfizer, or Amgen?
Merck has significantly outperformed its peers, Amgen and Pfizer, in 2026, with a 44% year-to-date gain, largely due to its oncology franchise and new product launches, rather than a GLP-1 obesity drug. Amgen secured second place with a 35% gain, while Pfizer lagged with 14% but offered a compelling 6.3% dividend yield. The article notes that Merck's success came despite the sector's focus on obesity drugs this year.
Gilead Sciences Inc Stock (GILD) Moved Up by 3.66% on Aug 19: A Full Analysis
Gilead Sciences Inc (GILD) saw its stock price increase by 3.66% due to strong performance in its HIV portfolio, favorable regulatory developments, and positive analyst ratings. The company's raised full-year sales guidance and a federal court injunction protecting its market share contributed to investor confidence. Despite some risks like acquisition-related earnings drag and heavy revenue concentration in its HIV franchise, technical indicators show a buy signal.
Pfizer Inc Stock (PFE) Moved Up by 3.96% on Aug 19: What Signal Does It Send?
Pfizer Inc. (PFE) stock rose by 3.96% following positive clinical trial results for an mRNA cancer treatment from Merck and Moderna, which validated mRNA technology for oncology and boosted investor confidence in Pfizer's own mRNA pipeline. The increase was further supported by Pfizer's strong second-quarter financial results, which exceeded Wall Street expectations, and management's raised full-year sales guidance and expanded cost-efficiency programs. Despite long-term challenges like patent expirations and leadership instability, positive clinical news and improved fundamentals contributed to the stock's significant move.
Novartis AG Stock (NVS) Moved Up by 3.82% on Aug 19: Key Drivers Unveiled
Novartis AG (NVS) saw its stock price rise by 3.82% on August 19, driven by strong quarterly financial execution and an expanding drug pipeline, particularly in oncology and cardiovascular treatments. Institutional investors favored the company due to its robust balance sheet and resilient margins, contributing to a broader sector rotation into defensive healthcare assets. Despite concerns about generic competition and legal risks, Novartis' strategic focus on cutting-edge therapies like radiopharmaceuticals has maintained investor confidence.
Merck's Large Late-Stage Pipeline Is Building Solid Defense Against Keytruda's Patent Cliff
Merck's extensive late-stage pipeline is poised to mitigate the impact of Keytruda's patent expiration in the late 2020s. While some sales declines are anticipated, new drug launches are expected to limit this period to roughly two years between 2029-2030. The company's strategic drug development is now yielding significant new products, ensuring strong returns on invested capital over the long term.
Moderna’s Cancer Breakthrough Just Made Tempus AI’s $1.5 Billion Bet Look Brilliant
Moderna and Merck's successful Phase 3 trial for a personalized mRNA cancer vaccine, intismeran autogene, has validated Tempus AI's $1.5 billion acquisition of Personalis. Personalis's NeXT Personal technology, an ultrasensitive minimal residual disease (MRD) test, is integral to the vaccine, and the trial's positive results have significantly boosted Tempus AI's stock and confirmed the strategic value of the merger. Tempus AI views MRD as a core strategic priority within a "20 billion plus market," with Personalis bringing substantial clinical diagnostic growth and Medicare-covered indications.
Stock Traders Buy High Volume of Merck & Co., Inc. Call Options (NYSE:MRK)
Merck & Co., Inc. (NYSE:MRK) experienced unusually high call option trading, with investors purchasing 68,587 call options, an increase of 188% over the average volume. This surge in bullish sentiment follows positive Phase 3 trial results for a Merck-Moderna melanoma vaccine combination, which significantly improved recurrence-free survival compared to Keytruda alone. Despite the stock rising 11.6% to $150.85, exceeding its average price target of $135.50, analysts are still awaiting complete trial data, including details on durability, safety, and commercialization.
Huge Unusual Put Options Volume in Merck - Is MRK Stock Overvalued?
Despite a 10% surge in Merck (MRK) stock following strong Q2 results and a successful drug trial, an unusually high volume of put options has traded at a much lower strike price of $135.00, prompting questions about whether the stock is overvalued. Analysts' price targets suggest a potential overvaluation, with current P/E ratio being high, but normalized EPS for future years indicates a more reasonable forward P/E. The author suggests that shorting puts could be a viable strategy, offering a potential 3% yield over three months and a good breakeven point.
MERCK CO INC
Shares of Moderna and Merck saw significant gains after a successful melanoma vaccine trial. Moderna's shares more than doubled, reaching an intraday record, while Merck's shares climbed over 10 percent. The article also touches on the emerging biosimilars market in Canada.
Moderna shares double as cancer vaccine data rekindles investor hopes
Moderna's shares more than doubled, adding $30 billion to its market value, after positive late-stage data for its personalized mRNA cancer therapy developed with Merck. This success is critical for Moderna to demonstrate the broader applicability of its mRNA technology beyond COVID-19 vaccines and infectious diseases. The therapy, intismeran, significantly reduced the risk of recurrence and spread of skin cancer when combined with Merck's Keytruda, leading to substantial gains for Moderna and Merck, and causing significant losses for short sellers.
Why Is BioNTech Stock Surging on Wednesday?
BioNTech's stock surged on Wednesday, likely due to positive topline data released by Merck & Co Inc. and Moderna for their individualized cancer therapy. This therapy, which showed significant improvements in recurrence-free and distant metastasis-free survival for advanced skin cancer, uses a mechanism similar to BioNTech's own individualized mRNA cancer immunotherapy candidate, Autogene cevumeran. BioNTech also shared promising three-year follow-up data for Autogene cevumeran in pancreatic cancer, and expects multiple late-stage cancer data readouts in 2026.
Novavax Stock Moves Higher Wednesday: What's Driving the Action?
Shares of Novavax Inc (NVAX) are trading higher due to a major clinical breakthrough in oncology by Merck & Co Inc and Moderna Inc. This success, specifically in an individualized mRNA cancer vaccine combined with Keytruda for advanced melanoma, has generated widespread positive momentum across the biotechnology sector. Novavax's proprietary Matrix-M adjuvant platform is also seen as a valuable asset, further supporting its rally.
Is AbbVie Stock About To Break Out Again?
AbbVie (ABBV) stock is trading at the top of its 52-week range, driven by the potential for a new subcutaneous induction option for its immunology drug SKYRIZI in Crohn's disease, which is currently under regulatory review. This dosing change is expected to accelerate SKYRIZI sales, a drug that already accounts for nearly a third of AbbVie's guided revenue and has seen its sales forecast raised twice this year. The company anticipates the commercial impact of this change to materialize in early 2027, potentially leading to further stock re-rating.
